Previous close | 65.27 |
Open | 65.50 |
Bid | 61.73 x 100 |
Ask | 67.97 x 100 |
Day's range | 64.64 - 66.35 |
52-week range | 64.64 - 87.87 |
Volume | |
Avg. volume | 7,349,480 |
Market cap | 81.689B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | 14.56 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 3.08 (4.72%) |
Ex-dividend date | 14 Mar 2024 |
1y target est | N/A |
Q1 2024 Gilead Sciences Inc Earnings Call
Explore Gilead's latest financial performance and strategic directions, including updates on HIV, oncology, and liver disease segments.
Although the revenue and EPS for Gilead (GILD) give a sense of how its business performed in the quarter ended March 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.